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Objectives: To describe survival, predictors of long-term outcome and attitudes in
patients treated at home by tracheostomy-intermittent positive-pressure ventilation
(TIPPV) for respiratory failure during a 10-year period (1995–2004).
Methods: Seventy-seven consecutive patients were treated by TIPPV at home. Patients
were divided into three groups: neuromuscular, pulmonary, and non-pulmonary patients.
Effects of TIPPV on survival, factors influencing outcome after TIPPV, and attitudes of
patients and caregivers regarding mechanical ventilation were studied.
Results: Forty-one patients (53%) were neuromuscular, 19 (25%) were affected by
pulmonary diseases, and 17 (22%) by non-pulmonary diseases. The median survival time
after TIPPV in the group was 49 months (range 3–149 months). There was statistically
significant longer survival in neuromuscular compared to pulmonary patients (p ¼ 0.006),
and a trend toward longer survival for non-pulmonary when compared to pulmonary
patients (p ¼ 0.048). Chronic obstructive pulmonary disease (COPD) patients (n ¼ 14)
showed the poorest outlook (median survival 26 months, range 3–45 months) and the
highest number of emergency readmissions to hospital. The median survival in
amyotrophic lateral sclerosis (ALS) patients was 49 months (range 30–61), lower than
the whole group of neuromuscular patients. Major tracheostomy complications were low:
2.6%. Multivariate analysis showed that COPD and ALS patients had a three-fold higher risk
of death than patients with other diagnoses. Lastly, 64 patients (83%) were pleased they
had chosen TIPPV and 69 (90%) would choose it again. Forty-two caregivers (55%) were
pleased the patients had chosen home ventilation, but 29 (38%) reported major burdens.Elsevier Ltd. All rights reserved.
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periods of time. Underlying conditions (COPD and ALS) might represent important
prognostic factors for survival.
& 2007 Elsevier Ltd. All rights reserved.Introduction
After the introduction of non-invasive mechanical ventila-
tion (NIV), and the development of more comfortable and
sophisticated prostheses, such as nasal and oro-nasal
masks,1 the indications to tracheostomy-intermittent posi-
tive-pressure ventilation (TIPPV) changed.2,3 At the present
time, TIPPV remains the elective procedure only in patients
with uncontrollable airway secretions, impaired swallowing
leading to chronic aspiration and repeated pneumonias, very
long periods of ventilation per day, facial dysmorphisms, and
in those patients placed on TIPPV in emergency, and who
later refuse to change the system of ventilation or cannot be
weaned.2
Ideally, the preferred location for long-term mechanical
ventilation is in the home, because costs are reduced,
quality of life is enhanced, and integration into the
community is maximized.2 However, there are few studies
that have investigated survival rate, ventilator complica-
tions, and physiologic consequences of care associated with
home TIPPV.2 Moreover, additional research should be
conducted to determine the predictors of success and
outcomes of TIPPV to improve the clarity of indications for
this type of ventilatory assistance.2
Finally, although the family usually provides most of the
support, and assumes the role of primary caregiver,
attitudes of patients and carers towards TIPPV have so far
received limited attention.4–6
We decided to conduct a prospective study aimed at
addressing survival times of patients placed on TIPPV and
cared for at home. In addition, we tried to identify potential
parameters significantly associated with survival after TIPPV,
and to investigate the attitudes of patients and their caregivers
regarding tracheostomy and mechanical ventilation.
Methods
Patients and procedures
We prospectively studied consecutive patients with respiratory
failure, treated with TIPPV between January 1995 and
December 2004, at Ospedale Civico ARNAS of Palermo. The
study was approved by the institutional review board. Oral
consent was obtained from all participants. Patients that were
able to be extubated or weaned from tracheostomy and placed
on non-invasive ventilation were excluded from the study.
The indications to TIPPV were as follows:(1) Elective procedure: patients with uncontrollable airway
secretions and very long periods of ventilation per day;
facial dysmorphisms; very long periods of ventilation per
day in patients who were not tolerant to non-invasive
ventilation.(2) Emergency procedure: patients who later refused to
change the system of ventilation (invasive to non-
invasive) or could not be weaned.We also divided the study into two periods: first period,
1995–1999, when we used volume ventilator and cuffed
tracheostomy tubes; second period, 2000–2004, when our
approach changed and we began to use pressumetric
ventilator and cuffless tracheostomy tubes.
The clinical and demographic features of the presentation
were collected for each patient, including: age, sex, enteral
feeding procedures, type of ventilator (volume-limited or
pressure-cycled) type of tracheostomy tube (cuffed or
cuffless), TIPPV in first (1995–1999) or second (2000–2004)
5-year period of study, number of hospital readmissions
because of acute deterioration, and tracheostomy-related
complications. Patients were evaluated at regular intervals
(every 3 months) with standardized medical evaluation,
including measurement of arterial blood gases. Patients
ventilated for 20 h/day or more were provided with a
supplementary backup ventilator for emergency use in case
of breakdown. Standard supply also included the manual
balloon ventilator (AMBU type) for emergency use, care-
givers being trained to use it if necessary. Suction apparatus
(suction machine, suction catheters, and connecting tubing)
was included in their equipment.
All the patients were treated for at least 24 months from
TIPPV, if they were alive, or until death, and the primary
outcome of the study was death (before December 31,
2006).
Patients were divided according to the underlying condi-
tions into three groups: neuromuscular, pulmonary, and non-
pulmonary patients.
Interviews and questionnaires
The structured patient interview included open- and closed-
ended questions. The patient questions encompassed
demographic items and details about ventilator use, daily
activities, lifestyle changes, and the mechanical ventilation
decision.
In separate interviews, family caregivers were asked
about the number of people involved in the patient’s daily
care, the benefits and burdens of mechanical ventilation for
families, and their attitudes regarding TIPPV for the patient.
All the interviews were carried out between 3 and 9 months
after TIPPV. All patients and caregivers answered the
questionnaire.
Data analysis
For statistical analyzes, we used the software SPSS version
10.0 to generate descriptive data and compile regression
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Table 1 Demographic and clinical characteristics of the 77 patients with respiratory failure at TIPPV start.
Characteristic Overall
(n ¼ 77)
Neuromuscular
diseases
(n ¼ 41)
Pulmonary
diseases
(n ¼ 19)
Non-pulmonary
diseases
(n ¼ 17)
p-Values
Age (years, mean7SD) 58.2717.5 55.8717 68.377.6,y 52.9722.2 0.011
Male gender 54 (70%) 33 (80.5%) 15 (79%) 6 (35%) 0.02
Enteral feeding 26 (34%) 21 (51%) 0 5 (29.5%) 0.004
Ventilation modality (volume
guaranteed pressumetric mode)
23 (30%) 14 (34%) 5 (26%) 4 (23.5%) 0.671
Cuffless tracheostomy tubes 23 (30%) 12 (29%) 5 (26%) 6 (35%) 0.835
Mean number of emergency hospital
readmissions
0.81 0.32 2z,y 0.59 0.0001
Tracheostomy-related complications 2 (2.6%) 2 (5%) 0 0 –
TIPPV in first 5-year (1995–1999) 38 (49%) 20 (49%) 10 (52.6%) 8 (47%) 0.94
Statistically significant (0.003) versus neuromuscular diseases.
yStatistically significant (0.008) versus non-pulmonary diseases.
zStatistically significant (0.0001) versus neuromuscular diseases.
yStatistically significant (0.002) versus non-pulmonary diseases.
S. Marchese et al.432models and graphs. One-way ANOVA and Kruskal–Wallis tests
were performed to compare quantitative variables between
groups and, when the test resulted significant, multiple
comparisons were carried out using the Dwass-Steel-Crit-
chlow-Fligner method. The w2 test was used to compare
qualitative variables. Data is reported as mean (S.D.) or
median (interquartile range). Analysis of survival was
undertaken using the Kaplan–Meier method, applying the
log rank test for differences between groups. Cox’s propor-
tional hazard regression model (backward stepwise) was
used to assess the effects of patient-related factors on
survival. The p-values less than 0.05 were considered as
significant.
Results
Demographic and clinical characteristics of the
patients
Seventy-seven patients were included in the study. The main
demographic and clinical characteristics of the patients are
reported in Table 1. Forty-one (53%) were neuromuscular
patients, 19 (25%) were affected by pulmonary diseases, and
17 (22%) were affected by other non-pulmonary diseases.
Neuromuscular diseases included the following: amyotrophic
lateral sclerosis (ALS, n ¼ 30), muscular dystrophies (n ¼ 5),
myasthenia gravis (n ¼ 3), spinal muscular atrophy (n ¼ 3).
In this group of patients, the age distribution was bimodal:
ALS or myasthenia gravis mean age was 61.978.4 years and
muscular dystrophy or spinal muscular atrophy mean age
was 25.1715.1 years. Pulmonary diseases included chronic
obstructive pulmonary disease (COPD, n ¼ 14), bronchiec-
tasis (n ¼ 2), silicosys (n ¼ 2), pulmonary radionecrosis
(n ¼ 1). Non-pulmonary conditions included chest wall
deformities (n ¼ 6), obesity hypoventilation syndrome
(n ¼ 3), tuberculosis sequelae (n ¼ 2), genetic defects
(n ¼ 6). As shown in Table 1, pulmonary patients were older(p ¼ 0.011) and had a higher proportion of hospital read-
missions (p ¼ 0.0001). Enteral feeding procedures were
more common in neuromuscular patients (p ¼ 0.004). Non-
pulmonary patients were more commonly female when
compared to the two other groups (p ¼ 0.002). Patients in
the three groups were similar in terms of type of ventilator
used, cuffed or cuffless tracheostomy tubes, and first or
second 5-year period of observation. Tracheostomy compli-
cations were recorded in two cases only (2.6%), and were
related to the development of a tracheo-esophageal fistula,
which in one case was also associated with tracheal stenosis.
Both the patients were on cuffed tracheostomy and
nasogastric feeding tubes. One of these patients was
successfully treated by switching to a cuffless tracheostomy
tube and his nasogastric tube removed, whereas the other
patient, who was in a terminal state because of the
progressive underlying disorder, died shortly afterwards.Survival analysis
For the whole group of patients, the median survival time
after TIPPV was 49 months (range 3–149 months). When we
divided the whole group of patients into the three groups
according to underlying conditions (neuromuscular, pulmon-
ary, and non-pulmonary diseases), we found that there was
statistically significant longer survival in neuromuscular
when compared to pulmonary patients (p ¼ 0.006, Figure 1).
Non-pulmonary patients showed a trend toward longer
survival when compared to pulmonary patients (p ¼ 0.048,
Figure 1). No significant difference in survival was found
between neuromuscular and non-pulmonary patients
(p ¼ 0.845, Figure 1). As shown in Figure 2, the poorest
survival rate was observed in COPD patients (n ¼ 14), with a
median of 26 months (range 3–45 months), and ALS patients
(n ¼ 30), with a median of 49 months (range 30–61 months),
both significantly lower than all the other patients (COPD
patients vs. other patients (p ¼ 0.0001), ALS patients vs.
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Figure 1 Long-term survival after TIPPV according to the
underlying conditions (neuromuscular, pulmonary, non-pulmon-
ary diseases). Neuromuscular and non-pulmonary patients
showed a significant longer survival compared to pulmonary
patients (p ¼ 0.006 and p ¼ 0.048, respectively).
Figure 2 Comparison of survival between COPD patients
(n ¼ 14) ALS patients (n ¼ 30) and the other diagnostic groups
(n ¼ 33). COPD and ALS patients showed a significant lower
survival (Copd vs. other patients (p ¼ 0:0001), ALS patients vs.
other patients (p ¼ 0:02)).
Table 2 Multivariable model of survival after TIPPV.
Variable Risk ratio (95%
confidence
interval)
p-Value
Underlying condition
(pulmonary disease
and/or ALS)
3.01 (1.18–7.68) 0.021
Female sex 0.52 (0.19–1.36) 0.084
Age 1.08 (0.98–1.15) 0.093
Outcome and attitudes toward home tracheostomy ventilation of consecutive patients 433other patients (p ¼ 0.021)). Survival after TIPPV was also
significantly lower for COPD patients compared to ALS
patients (p ¼ 0.005).Factors influencing survival after TIPPV
We performed multiple regression analysis with the Cox
stepwise proportional hazards model to identify indepen-
dent predictors of survival after TIPPV. We found that the
underlying condition (COPD or ALS) was the most important
predictor of survival, with patients with COPD or ALS
showing a three-fold greater risk of death as compared to
those with other diagnoses (Table 2). A trend toward
significance was also seen for age at respiratory failureand female sex (Table 2). None of the other variables
examined, including proportion of hospital readmissions,
type of ventilatory device used, cuffed or cuffless tra-
cheostomy tubes, and first or second 5-year period of
observation, were significantly related to survival rate.
Attitudes toward home ventilation
Sixty-four patients (83%) were pleased they had chosen
invasive ventilation and 69 (90%) would choose it again. At
the time of the interview, five patients (7%) reported TIPPV
changed their lifestyle, mainly because of progressive
inability, related to the underlying pathology.
The primary caregivers of all the patients were family
members. Of the 77 caregivers, 62 (80.5%) were women, and
this was not surprising given the high preponderance of male
patients included in the study. Fifty-five were spouses,
eighteen were parents, three were boys, and one was a
close friend. On average, families provided 12 h (‘‘real
time’’) of care daily. Forty-two caregivers (55%), including
all the carers that were also parents of the patient, were
happy with the patients’ choice, and would encourage them
to choose it again. Twenty-nine (38%) considered it a major
burden to have the patient at home receiving mechanical
ventilation, because it affected their entire life-style,
increased the number of hours of assistance, and was very
stressful. Thirty-three (43%) reported that nighttime was
especially burdensome and stressful because of the pa-
tients’ anxiety and chronic insomnia, probably related to
the fear of unexpected sudden death.
Discussion
The results of our prospective study show that TIPPV is a
relatively safe intervention that allows long-term survival
for patients with respiratory failure, who cannot tolerate, or
have contra-indications for NIV. The high number of patients
in TIPPV (77 pt (29.7% of total patients)) in our center is due
to the transfer of some patients from other hospitals. In the
same period (1995–2004), 182 patients started NIV and
returned to the outpatients’ department after discharge. As
there is little data regarding the long-term outcome in
patients receiving TIPPV, our findings might be helpful in
making decisions about ventilatory support for respiratory
failure. Moreover, we found that the underlying condition
(COPD and ALS) was independently associated with survival,
suggesting that this variable may be useful in the prediction
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gated attitudes of patients and their caregivers regarding
TIPPV and we found that this procedure is widely accepted
and desired by the majority of patients who undergo it, but
imposes significant burdens on families.
The clinician’s approach to managing respiratory failure
depends on the patient’s desires concerning ventilatory
support. Over the last 15 years, we have witnessed a
progressive increase in the use of NIV worldwide, and TIPPV
is now the elective procedure only in selected patients.2,3
The main disadvantages of invasive ventilation are a
moderate increase in the risk of infection, a definite
risk of tracheal damage, such as tracheomalacia, tracheal
erosion, and tracheal rupture, speech alterations, and
increased costs and burden of assistance.1,2 However, TIPPV
is associated with a reduced risk of aspiration, may be more
comfortable when required for more than 20 h/day, and may
allow long-term survival for those patients choosing that
route.2
In this study, we have shown that patients on TIPPV
survived for many years. In line with previous studies,7–10
pulmonary patients (19 pt (25%)), especially COPD patients
(14 pt (18%)), showed the poorest survival rate. The
indication to tracheostomy in these groups of patients was
not the elective procedure. They could not be weaned and
some of them refused to change the system of ventilation
(invasive to non-invasive).
Although our patients with COPD were older than the
other diagnostic categories of patients on TIPPV, the
unfavorable prognosis of COPD patients remained even after
being adjusted for age. The indication to NIV in COPD
patients is not clear,1–2 and the studies about survival in
COPD with NIV were negative; only the reduction of daytime
gas exchange and quality of life score9–10 proved. In a
European survey,11 about 34% of home mechanical ventila-
tion was COPD and the use of tracheostomy varied
considerably between countries. In our institution, only
10% of non-invasive ventilation users are COPD, and they
have elevated values of PaCO2 in a stable condition and with
repeated hospitalizations.
Different results were observed by Muir et al.,14 in an
‘‘old’’ study (1994), which reported longer actuarial survival
in COPD patients, 70% of the patients surviving at 2 years,
and 44% at 5 years. Certainly, diversities in the severity of
the disease in the populations studied could contribute to
the differences observed in the studies, since in the
research by Muir et al.14 tracheostomy was performed
in election when patients were probably in less serious
conditions.
On the other hand, neuromuscular patients survived for a
very long time, with a median of 5 years, which was not
different from non-pulmonary patients. In our study, the
neuromuscular group was composed mainly of ALS patients,
and similar survival rates have also been reported by other
groups.15,16,17 Votto et al.,12 on the contrary, reported a
median survival of 17 months in neuromuscular patients on
TIPPV, which could be explained by the more severely
impaired population studied, since patients, because of
their medical complexity, required high-acuity hospital care
and/or related infection. When we evaluated survival only
in ALS patients, we noted the increased survival as
compared to ALS patients in NIV in our institution29 (mediansurvival: TIPPV 49 months vs. NIV 18 months for tolerant
patients and 6 months for intolerant patients). Interestingly,
the survival rates of our ALS patients are in line with
previous studies on TIPPV in ALS.4–15
When we tried to assess whether any differences in
survival might be observed in relation to the type of
ventilator, tracheal cannula, or different 5-year period of
observation, we found no significant differences. Moreover,
we found that tracheostomy-related complications were
few, and the general number of readmissions to hospital
because of emergency was low. COPD patients, however,
showed significantly higher rates of readmission than the
other groups, suggesting that home management could be
less useful in this kind of patient. This hypothesis is
confirmed by low survival-rates in COPD. In a large multi-
center study reporting data from 259 COPD patients
receiving mechanical ventilation at home, Muir et al.14
reported a higher number of complications that were more
common in patients with cuffed tracheostomy tubes. In our
study, the survival rate was the same in both groups, cuffed
and cuffless. This indicates that to use cuffless tracheostomy
tubes can help reduce tracheal complications and swallow-
ing dysfunctions,22 improving patients’ speech.23–25
Another important aspect that we investigated in this
study regards the factors potentially related to survival
after invasive ventilation. We found that the underlying
condition (COPD or ALS) was the most important factor
significantly related to survival after TIPPV. Our study
suggests that the outcome after invasive ventilation is
heavily influenced by the disease that caused respiratory
insufficiency, and strengthens the notion that pulmonary
patients, especially COPD, display the worst survival rates.
Female sex, and, to a lesser extent, age at the beginning
of TIPPV, also showed a trend toward significance, suggest-
ing that female patients, even if less numerous than males,
may survive longer. This interesting result, already reported
by others,18–23 could be partially related to the low
prevalence of COPD or ALS among female patients, but
clearly demonstrates that great efforts should be made to
support all the patients that choose to undergo TIPPV.
Future studies are needed to confirm these interesting
findings.
Finally, we investigated patient satisfaction with TIPPV
and attitudes in both patients and their caregivers. Although
many patients might prefer NIV to TIPPV,19,20 in line with
previous studies conducted prevalently on ALS patients,4,5
we noted that patients receiving TIPPV at home were
satisfied with their choice, and would choose it again, even
if it frequently affected their lifestyle. Interestingly,
responses were very similar, regardless of the underlying
conditions, suggesting that satisfaction could be related to
spiritual and perhaps religious aspects, rather than physical
functions. Our data is in agreement with Soudon21 when he
says: ‘‘Tracheostomy can be the best or the worst system of
ventilation. When it is a success, it is probably the most
compliant method for people who accept it.’’
On the other hand, our results support the notion that
home ventilation poses a great strain on family members.5,6
Only half of the caregivers were glad the patients
had chosen home ventilation, and would encourage the
patient to choose it again. Many were not satisfied and
heavily burdened by the stressful activities of home care.
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with nighttime care and assistance, because of the patients’
anxiety and chronic insomnia, and many related these
problems to the patients’ fears of sudden and unexpected
death.
The age of patients could play an important role in the
caregiving experience, especially in neuromuscular dis-
eases, which can frequently affect children or adolescents
at the time of TIPPV. The high motivation of parents for the
care of their children in home often results in a high quality
of care, and many children will experience a near-normal
lifestyle.2 Our results confirm that when the carers are the
patient’s parents, they seem to be more willing to spend
their time in assistance, are quite satisfied, and find it all
less of a burden than caregivers of adult patients. However,
the stress that caregivers undergo requires the help of
health professionals to provide strong psychosocial support
for families, including access to mental health professionals
for both the ventilator-assisted children and the caregivers,
as well as a plan for respite care.2
There are several limitations to this study. Firstly,
we reported data from a relatively limited number of
patients and with different types of diseases within the
group; the survival rate might be different in homogeneous
single groups. Secondly, the study was limited to only
one geographical region; home ventilation practices and
satisfaction may differ elsewhere. Thirdly, we evaluated
the caregivers’ answers overall, but the pathologies were
very different as were the age of incidence and caregivers’
ages (in neuromuscolar diseases, the situation is very
different if we are analyzing ALS or Duchenne). Finally,
we did not attempt to measure quality of life in the
assessment of patients’ and caregivers’ attitudes toward
home ventilation, because the study started in 1994;
today, the situation is completely different and quality of
life studies would be needed using Maugeri Foundation
Respiratory Failure Questionnaire (MRF-28) (which is applic-
able to patients with both obstructive and restrictive
disorders26 or Severe Respiratory Insufficiency (SRI) Ques-
tionnaire.27 In our opinion, individual studies are necessary
for each pathology as Kohler et al.28 have shown in
Duchenne patients.
In conclusion, we found that TIPPV is a relatively safe
procedure, and allows long-term survival for the patients
that undergo it. Patients are usually satisfied, even though it
does place a great burden on caregivers. Underlying
conditions (COPD and ALS) might represent important
prognostic factors for survival.Conflict of interest statement
The authors have reported no conflicts of interest.References
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